Trials / Recruiting
RecruitingNCT06560112
An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 172 (estimated)
- Sponsor
- Akeso · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
Detailed description
This is a Phase 2, open label, multicohort, multicenter study designed to evaluate the efficacy and safety of combination therapy of AK104, AK112 and chemotherapy in recurrent ovarian cancer. AK104 is a bispecific monoclonal antibody targeting both CTLA-4 and PD-1. AK112 is a bispecific monoclonal antibody targeting VEGF and PD-1.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK104 | ivgtt |
| DRUG | AK112 | ivgtt |
| DRUG | Chemotherapy | ivgtt |
Timeline
- Start date
- 2024-11-12
- Primary completion
- 2026-05-01
- Completion
- 2027-05-01
- First posted
- 2024-08-19
- Last updated
- 2025-03-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06560112. Inclusion in this directory is not an endorsement.